UBS Group
ACRS icon

UBS Group’s Aclaris Therapeutics ACRS Stock Holding History

UBS Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,400
Closed -$148K – 9460
2021
Q2 		$148K Hold
8,400
– – ﹤0.01% 5578
2021
Q1 		$212K Buy
+8,400
New +$164K ﹤0.01% 5441
2019
Q3 		– Sell
-103,000
Closed -$226K – 7947
2019
Q2 		$226K Buy
+103,000
New +$561K ﹤0.01% 4847

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group's ACRS Position: Q1 2026 in Review

UBS Group reduced its Aclaris Therapeutics (ACRS) stake by 43% in Q1 2026, selling an estimated $525K and leaving 206,814 shares worth $776K. The position accounts for ﹤0.01% of the portfolio, ranked #5752.

UBS Group first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $9.73M in Q4 2018. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • UBS Group held 206,814 shares of Aclaris Therapeutics worth $776K as of Q1 2026.
  • UBS Group sold 155,724 Aclaris Therapeutics shares in Q1 2026, an estimated $525K.
  • Aclaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5752 holding.
  • UBS Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • UBS Group's Aclaris Therapeutics position peaked at $9.73M in Q4 2018.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.